I think who I will definitely use it for is for patients who have functional high-risk or high-risk disease, because again with myeloma therapy, we see an attrition at every stage. Many second-line patients never make it to third line because disease becomes so aggressive, it's impossible to rescue and their functional status deteriorates, so people who are progressing very quickly after frontline therapy, and this is a moving target. We used to say 18 months or 24 months, but that was with VRd-type therapies [bortezomib (Velcade)/lenalidomide (Revlimid)/dexamethasone]. Now we have quadruplet therapies, which by the way were not very common. Most of these patients were on Dara, and they couldn't be Dara-refractory, and only a quarter of these patients were Dara-exposed in CARTITUDE-4 [ NCT04181827 ].